<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00045500</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000256599</org_study_id>
    <secondary_id>NCI-02-C-0241</secondary_id>
    <secondary_id>NCI-5694</secondary_id>
    <nct_id>NCT00045500</nct_id>
    <nct_alias>NCT00041873</nct_alias>
  </id_info>
  <brief_title>UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma</brief_title>
  <official_title>A Phase I Trial Of UCN-01 And Prednisone In Patients With Refractory Solid Tumors And Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: UCN-01 may stop the growth of cancer cells by blocking the enzymes necessary for&#xD;
      cancer cell growth. Drugs used in chemotherapy use different ways to stop cancer cells from&#xD;
      dividing so they stop growing or die. Combining UCN-01 with prednisone may kill more cancer&#xD;
      cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combining UCN-01 with prednisone in&#xD;
      treating patients who have refractory solid tumors or lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of UCN-01 in combination with prednisone in&#xD;
           patients with refractory solid tumors or lymphomas.&#xD;
&#xD;
        -  Determine the toxic effects of this regimen in these patients.&#xD;
&#xD;
        -  Assess the pharmacokinetics of this regimen in these patients.&#xD;
&#xD;
        -  Assess any tumor response in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of UCN-01.&#xD;
&#xD;
      Patients receive oral prednisone daily on days 1-5 and UCN-01 IV over 36-72 hours on days&#xD;
      3-5. Courses repeat every 28 days for up to 2 years in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of UCN-01 until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3&#xD;
      or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the&#xD;
      recommended phase II dose.&#xD;
&#xD;
      Patients are followed every 3-12 months for 5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 24 patients will be accrued for this study within 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lymphoma</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>7-hydroxystaurosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed solid tumor or lymphoma&#xD;
&#xD;
               -  Progressive disease after standard therapy&#xD;
&#xD;
               -  No other therapy is likely to improve survival&#xD;
&#xD;
          -  Prostate cancer patients must have progressed through hormonal therapy with&#xD;
             gonadotropin-releasing hormone (GnRH) agonists and withdrawal of testosterone receptor&#xD;
             antagonists&#xD;
&#xD;
               -  Patients must continue on GnRH agonist during study (if orchiectomy has not been&#xD;
                  performed) and have castrate testosterone levels&#xD;
&#xD;
          -  Brain metastases allowed if treated and the patient has been stable off anti-seizure&#xD;
             medication or steroids for &gt; 6 months&#xD;
&#xD;
          -  No local complications from disease requiring urgent therapy (i.e., hydronephrosis,&#xD;
             spinal cord compression, or severe pain requiring improved pain management)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,000/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  12-hour fasting glucose no greater than 110 mg/dL OR&#xD;
&#xD;
          -  12-hour fasting glucose no greater than 140 mg/dL with hemoglobin A1C no greater than&#xD;
             6.5 mg/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  PT/PTT no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times ULN (unless Gilbert's syndrome present)&#xD;
&#xD;
          -  AST/ALT no greater than 2.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min OR&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No interstitial lung disease within the past year&#xD;
&#xD;
          -  No requirement for oxygen therapy for hypoxia in the past 6 months&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  No diagnosis of duodenal or gastric ulcer&#xD;
&#xD;
          -  No severe gastritis within the past 6 months&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No prior allergic reactions to other indolocarbazoles&#xD;
&#xD;
          -  No diabetes or hyperglycemia within the past year that required a diabetic diet, oral&#xD;
             hypoglycemics, or insulin&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No seizure disorder&#xD;
&#xD;
          -  No psychiatric illness that would preclude study compliance&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 2 months after study&#xD;
             therapy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
          -  No prior UCN-01&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No other concurrent oral or IV steroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 21 days since prior major surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni Melillo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute - Frederick</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NCI - Center for Cancer Research</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frederick Cancer Research and Development Center</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21702-1201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2005</verification_date>
  <study_first_submitted>September 6, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>April 29, 2015</last_update_submitted>
  <last_update_submitted_qc>April 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2015</last_update_posted>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>intraocular lymphoma</keyword>
  <keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>7-hydroxystaurosporine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

